Early Alzheimer’s disease is a condition that affects memory and thinking skills, usually beginning with mild problems that gradually become more noticeable. The study investigates an oral medication called SAR448851, which is taken as a hard capsule, and compares it to a matching placebo that looks the same but does not contain the active drug.
The purpose of the study is to evaluate the safety and effectiveness of SAR448851 in people with early Alzheimer’s disease. Participants will take the study medication every day for about 48 weeks, during which they will have regular visits for simple blood tests that measure a protein called p‑tau217, a marker that can show changes related to the disease, and may also undergo a brain scan to look for amyloid plaques, which are tiny buildups associated with Alzheimer’s. After the first 48 weeks, participants may choose to continue in an open‑label phase, where everyone receives the active medication, for up to another year, with continued monitoring.
Throughout the trial, safety is closely watched by checking for any side effects, measuring vital signs, and performing routine laboratory tests. Any serious problems are recorded, and participants can stop the study at any time if needed.
Spain 